Logo

Advanced Bio/Chem Licenses Breast Cancer Biomarker Technology from M.D. Anderson

Mar 16, 2004

NEW YORK, March 16 (GenomeWeb News) - Advanced Bio/Chem has licensed breast cancer protein biomarker technology from the University of Texas' M.D. Anderson Cancer Center, the company said today.

 

ProteEx, located in The Woodlands, Texas, is doing business as Advanced Bio/Chem.

 

The technology, relying on proteomic analysis of breast ductal fluids, was jointly developed by the company and UT M.D. Anderson.

Breaking News
The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.